Starpharma (SPHRY) Stock Price, News & Analysis

Company Overview

Starpharma is a clinical-stage biopharmaceutical company specializing in the development of dendrimer-based products across infectious disease, oncology and ophthalmology. Its proprietary dendrimer platform, DEP™ (Dendrimer Enhanced Products), enables precise molecular engineering to enhance drug delivery, targeting and safety profiles. The company’s lead product, VivaGel®, is a topical microbicide that has been approved in multiple markets for the treatment and prevention of bacterial vaginosis and is in clinical development for antiviral applications.

In addition to VivaGel, Starpharma is advancing pipeline candidates that leverage DEP technology to improve the performance of established and novel therapeutic agents. These include an antiviral nasal spray for respiratory viruses and investigational oncology conjugates designed to selectively deliver cytotoxic drugs to tumor cells. The adaptable nature of the dendrimer platform allows Starpharma to tailor its technology for diverse therapeutic areas.

Starpharma has forged strategic partnerships and licensing agreements with leading pharmaceutical companies to commercialize and co-develop DEP-enhanced products. Collaborations include deals with AstraZeneca and Mundipharma for support of antibacterial and oncology candidates, as well as academic and governmental research collaborations aimed at broadening the application of dendrimer technology in global health.

Founded in 2000 and headquartered in Melbourne, Australia, Starpharma serves markets in North America, Europe and Asia Pacific through its own operations and partner networks. The company is led by CEO Jackie Fairley, whose background in biopharmaceutical research and development has guided Starpharma’s growth from an early-stage innovator to a diversified clinical-stage company.

Key Stats

• Today's Range: $5.10 to $5.10
• 50-Day Range: $3.00 to $5.70
• 52-Week Range: $0.55 to $5.70
• Volume: N/A
• Average Volume: 905 shs
• Market Capitalization: $214.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 6/10/2026
• Fiscal Year End: 6/30/2026
• Next Earnings (Estimated): 8/26/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SPHRY
• CIK: N/A
• Web: www.starpharma.com
• Phone: (138) 532-2700
• Fax: 61-3-9510-5955
• Employees: 45
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $3.18 million
• Price / Sales: 67.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.29 per share
• Price / Book: 17.59

Miscellaneous

• Outstanding Shares: 42,090,000
• Free Float: N/A
• Market Cap: $214.66 million
• Optionable: Not Optionable
• Beta: 1.23